Rebiotix is highlighted in The Future of Healthcare series under the headline The Future of Healthcare: “In the future we might be able to take microbes from a healthy person and using them to cure sick people” With Lee Jones, CEO of Rebiotix Inc.…
Portfolio Company News
Thrive Global Recognizes Sofia Portfolio Company Oculogica
Oculogica is highlighted in the Community section under the headline The Future of Healthcare “Tracking a person’s eye movements to diagnose brain injuries” with Dr. Uzma Samadani of Oculogica. Read the entire article here:
Cognition Therapeutics Receives European Patent Covering its Alzheimer’s Disease Candidate, Elayta™
Pittsburgh, PA, February 21, 2019 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative diseases and disorders, today announced the issuance by the European Patent Office of a composition of matter patent covering Elayta™, Cognition’s lead clinical stage compound in development for individuals with Alzheimer’s disease. …
Oculogica mentioned in February 19, 2019 issue of JAMA
Oculogica is the first highlight of the JAMA news section in this week’s issue: https://jamanetwork.com/journals/jama/fullarticle/2725217
Cognition Therapeutics Announces Publication of Complete Results from Phase 1 Clinical Trial of Elayta™
Elayta Crossed Blood Brain Barrier and Reached CNS Levels Associated in Preclinical Studies with Cognitive Improvement
Pittsburgh, PA, February 19, 2019 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative disorders, announced today the publication of clinical data from the Company’s Phase 1 trial of Elayta™ (CT1812) in Alzheimer’s & Dementia: Translational Research & Clinical Interventions.…
Sofia Fund portfolio company Oculogica achieves FDA milestone
Oculogica receives FDA Marketing Authorization for EyeBOX®, the first non-invasive, baseline-free test for concussion. Oculogica is a pioneer in algorithm-based neurodiagnostics.
CogRX receives $16.6M Grant for Phase II Study of Alzheimer’s Drug
Sofia Fund portfolio company CogRX has received a $16.6M Multi-Year Grant for Phase II studies of its Elayta™ drug for mild-to-moderate Alzheimer’s disease. Learn more at CogRX announces NIA grant…
Looking Concussion in the Eye
A recent post in the April/ May Issue of MIT Review discusses the science Uzma Samadani used as she sought to find a way to measure improvements in her severely, brain-injured patients. The ability to capture a large amount of data from tracking not only eye movement but restrictions on range of motion in the eye led to the EyeBox product being developed by Oculogica, one of Sofia Fund’s portfolio companies.…
Getting a Read on Brain Function
Very interesting article in the StarTribune about HCMC’s neurosurgeon Dr. Uzma Samadani and the technology she is developing to assess brain function in real time. The technology is licensed to Oculogica, a company she co-founded, and is embodied in their device called the Eyebox.…